Treatment of Pseudomonas in Tracheostomy Tube Secretions

Diagnosis and Assessment

The European Respiratory Society notes that Pseudomonas aeruginosa colonization is characterized by the presence of the bacteria in the bronchial tree without signs of inflammation or infection 4
The European Respiratory Society defines active Pseudomonas infection as the presence of bacteria with direct signs, such as inflammation or fever, or indirect signs, such as a specific antibody response, of infection and tissue damage 4

The European Respiratory Society recommends nebulized antibiotics, such as tobramycin or colistin, as the mainstay of treatment for Pseudomonas colonization, with systemic antibiotics added for signs of active infection 1, 2, 3
The European Respiratory Society suggests that nebulized antibiotics should be administered using a compressor with a flow rate of 6 L/min, a breath-enhanced open vent nebulizer, and a mouthpiece rather than a face mask, except for young children 2
The European Respiratory Society recommends high doses of nebulized antibiotics to maximize reduction in P. aeruginosa colony counts, with typical regimens including tobramycin 25-600 mg per nebulization and colistin 500,000 to 3 MIU per nebulization 5

The European Respiratory Society recommends that nebulized antibiotics be prescribed twice daily for home use, with solutions that are not hypertonic and are reconstituted immediately before use 2
The European Respiratory Society emphasizes the importance of equipment care, including cleaning nebulizers after each use, disassembling and washing all parts, and changing standard equipment every three months 2

The European Respiratory Society notes that treatment duration for active infections typically ranges from 7-14 days, with most patients showing improvement well into the second week of therapy, and weekly pulmonary function testing and clinical observations guiding when to end treatment 5
The European Respiratory Society suggests that some evidence supports continuous or intermittent maintenance therapy to prevent exacerbations, with a month on/month off regimen with preservative-free tobramycin showing benefits in cystic fibrosis patients with chronic Pseudomonas infection 7

The European Respiratory Society recommends regular monitoring of respiratory secretions and cultures to track treatment efficacy, and monitoring for development of antibiotic resistance in patients on long-term therapy 5, 7